SCHEMBL3229148

SCHEMBL3229148

Clc1nc(NC2CCC2)cc(-c2ccccc2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
KMT2A Q03164 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
VCP P55072 1/20 0.48
KDM4E B2RXH2 3/20 0.48
CDC7 O00311 1/20 0.48
DBF4 Q9UBU7 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ADORA1 P30542 8/20 0.46
ADORA2A P29274 6/20 0.46
ADORA3 P0DMS8 3/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
GPR39 O43194 1/20 0.42
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3237770 0.97 SMN1; SMN2 (0.54) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL3450507 0.96 CDC7 (0.53) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL28531382 0.88 PIM1 (0.46) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL30321182 0.88 PIM1 (0.46) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL3450774 0.87 MEN1 (0.50) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL20576629 0.85 ADORA1 (0.46) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL28148108 0.84 ALDH1A1 (0.41) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL28544504 0.81 VCP (0.42) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL20576178 0.81 VCP (0.42) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL13309931 0.81 ADORA1 (0.63) SMN1; SMN2MEN1KMT2AVCPKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
WO-2010028179-A1 HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed
WO-2010028179-A1 HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS GATAD2B, GATAD2A, RUNX1 SMN1; SMN2 2766/4885MEN1 1320/4885ALDH1A1 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.